Compare Novo Nordisk A/S (NVO) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Vanguard S&P 500 ETF — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Vanguard S&P 500 ETF trades at $715.59 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 10.9× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Vanguard S&P 500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Vanguard S&P 500 ETF for 55 Days on average.
| NVO | VOO | |
|---|---|---|
Market Cap | $165.31B | $1.80T |
Volume | 11,432,838 | 4,722,271 |
Sector | Health | Broad Market / Factor |
52-Week High | $63.98 | $716.17 |
52-Week Low | $35.29 | $580.93 |
Typical Hold Time | 116 Days | 55 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
VOO trades at $711.37, down 0.43% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF maintains strong institutional support despite a 46.9% increase in short interest reported by Defense World on October 3, 2026. Recent news highlights VOO's role as a core holding for long-term wealth building, with dividend payments scheduled for September 30, 2026.
VOO offers diversified exposure to S&P 500 companies with strong earnings growth projections of 35% for 2026. While short-term volatility may persist amid Federal Reserve policy uncertainty, the ETF remains well-positioned for investors seeking broad market participation. Key risks include potential earnings growth deceleration to 15% in 2027 and broader market valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
